https://www.selleckchem.com/products/fiin-2.html
1% vs. 86.0% and 73.5% vs. 58.1%, respectively; 0.05). The primary patency rate at 12 months in the BVS group was significantly higher than that in the CBS group (61.8% vs. 32.6%; = 0.008). Endovascular treatment of central vein obstruction with BVS provided a higher primary patency rate at 12 months than CBS. Endovascular treatment of central vein obstruction with BVS provided a higher primary patency rate at 12 months than CBS. Non-invasive modalities for assessing axillary lymph node (ALN) are needed in clinical practice. To in
Like
Comment
Share
